Drawing for PLEXPCR

USPTO serial 79183454

PLEXPCR

Reviewed by CopyMark Law Group

Reg. 5215664Status 739Renewal
Filing date
Status date
Registration date
Jun 6, 2017
Examiner
MURRAY, DAVID T
Law office
GENERIC WEB UPDATE

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Need help with PLEXPCR?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $797*

Plus Government fees of $1,950

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Mainak H. Mehta

Mainak H. Mehta Procopio Cory Hargreaves & Savitch525 B Street, Suite 2200San Diego, CA 92101UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001Chemicals used in industry, science, photography; chemicals used in agriculture, horticulture and forestry except fungicides, herbicides, insecticides, and parasiticides; chemical reagents and reactants in this class for non-medical purposes; enzymes for industrial purposes, namely, for use in the biotechnology industry; nucleic acid sequences, other than medical and veterinary purposes; nucleic recombinant acids; acids, namely, inorganic acids; organic acids for use in the biotechnology industry; DNA polymerase, other than medical and veterinary purposes; chemicals used in food processing and screening; chemicals used in environmental monitoringACTIVE—
005Pharmaceutical and veterinary preparations and substances for the diagnosis of diseases or detection or identification of pathogens for medical and veterinary purposes; reagents for medical and veterinary use; nucleic acid amplification reagents for medical use; nucleic acid sequencing programs for medical use; chemical preparations containing enzymes for medical purposes for the diagnosis of diseases or detection or identification of pathogens; chemical preparations containing enzymes for pharmaceutical, veterinary and medical purposes for the diagnosis of diseases or detection or identification of pathogens; enzymes for pharmaceutical, veterinary and medical purposes; medical kits in this class consisting of catalytic DNA molecules and associated detection reagents for the diagnosis of diseases, for detection and identification of pathogens, for the detection of antibiotic resistance, for the analysis of gene expression, protein expression, metabolite expression, inflammation, and immune-suppression and immune disorders, for genotyping, analysis of polymorphisms, detection of acquired or inherited genetic mutations, detection and analysis of epigenetic alterations, and for analysis of response to therapy; diagnostic reagents for medical or veterinary use; biological chemical test kits for medical laboratory use in analysis of gene expression, protein expression, metabolite expression, inflammation, immune-suppression, immune disordersACTIVE—
010Surgical, medical and veterinary apparatus and instruments, namely, surgical apparatus and instruments for medical or veterinary use; diagnostic testing apparatus and instruments for medical purposes, namely, for the detection of diseases, detection and identification of pathogens, detection of antibiotic resistance, for the analysis of gene expression, protein expression, metabolite expression, inflammation, immune-suppression and immune disorders, for genotyping, for analysis of polymorphisms, detection of acquired or inherited genetic mutations, detection and analysis of epigenetic alterations, and for analysis of response to therapy; point of care medical devices for the detection of diseases, detection and identification of pathogens, detection of antibiotic resistance, for the analysis of gene expression, protein expression, metabolite expression, inflammation, immune-suppression and immune disorders, for genotyping, for analysis of polymorphisms, detection of acquired or inherited genetic mutations, detection and analysis of epigenetic alterations, and for analysis of response to therapy; medical screening apparatus in this class for the detection of diseases, detection and identification of pathogens, detection of antibiotic resistance, for the analysis of gene expression, protein expression, metabolite expression, inflammation, immune-suppression and immune disorders, for genotyping, for analysis of polymorphisms, detection of acquired or inherited genetic mutations, detection and analysis of epigenetic alterations, and for analysis of response to therapyACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jun 6, 2026REM4COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED—
Aug 7, 2025RNWLINTERNATIONAL REGISTRATION RENEWED—
Feb 14, 2024NA75NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED—
Feb 14, 2024C75AREGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.—
Feb 12, 2024APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Jun 6, 2023ES75TEAS SECTION 71 & 15 RECEIVED—
Oct 28, 2017FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Sep 13, 2017FICSFINAL DISPOSITION NOTICE SENT TO IB—
Sep 13, 2017FIMPFINAL DISPOSITION PROCESSED—
Sep 6, 2017FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Jun 6, 2017R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Mar 21, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 17, 2017GPNXNOTIFICATION PROCESSED BY IB—
Mar 10, 2017NREPNEW REPRESENTATIVE AT IB RECEIVED—
Mar 1, 2017OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Mar 1, 2017OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Mar 1, 2017NPUBNOTICE OF PUBLICATION—
Feb 13, 2017PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Feb 10, 2017NREPNEW REPRESENTATIVE AT IB RECEIVED—
Feb 2, 2017CNEAEXAMINERS AMENDMENT MAILED—
Feb 1, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Feb 1, 2017XAECEXAMINER'S AMENDMENT ENTERED—
Feb 1, 2017CNEAEXAMINERS AMENDMENT -WRITTEN—
Dec 20, 2016CNFRFINAL REFUSAL MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Dec 19, 2016CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Dec 16, 2016NREPNEW REPRESENTATIVE AT IB RECEIVED—
Dec 14, 2016TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Dec 14, 2016CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 9, 2016ALIEASSIGNED TO LIE—
Nov 29, 2016NREVNOTICE OF REVIVAL - MAILED—
Nov 28, 2016TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 28, 2016PETGPETITION TO REVIVE-GRANTED—
Nov 28, 2016PROATEAS PETITION TO REVIVE RECEIVED—
Oct 3, 2016MAB2ABANDONMENT NOTICE MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Oct 1, 2016ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Mar 19, 2016RFNTREFUSAL PROCESSED BY IB—
Mar 4, 2016MAFRAPPLICATION FILING RECEIPT MAILED—
Mar 2, 2016RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Mar 2, 2016RFRRREFUSAL PROCESSED BY MPU—
Mar 2, 2016RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Mar 1, 2016CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 29, 2016DOCKASSIGNED TO EXAMINER—
Feb 29, 2016NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Feb 25, 2016REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance